References
- Dance A. The challenges of antiviral treatments. Knowable Mag, Feb. 2021. doi: 10.1146/knowable-020821-2
- “Guidelines on evaluation of similar biotherapeutic products (SBPs), Annex 2, TRS No 977,” World Health Organization , Jan. 2010.
- “NHS England » Biosimilar medicines.”
- “Biosimilars,” FDA, Jan. 2023.
- Stewart J. What biosimilars have been approved in the United States? Drugs Com. 2023. https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/
- “Interferon Biosimilar Landscape Report, 2020 Featuring Zydus Cadila, Reliance Life Sciences, Profarma, Harvest Moon Pharmaceuticals, Dong-A ST, CinnaGen, BioPartners, Biocad, Amega Biotech - ResearchAndMarkets.com | Business Wire,”Sep. 2020.
- “EU accepts BioPartner’s interferon as first ‘biosimilar’ filing,” 2023.
- Calabrese LH“The cost of biosimilars, lessons from hepatitis C,” Aug. 2018.
- “Bioferon: uses, side effects, interactions, dosage.” Pillintrip, Mar. 2022.
- Ahmed W, Arif A, Alam E, et al. Response to different conventional interferons in treatment of chronic hepatitis C. J Ayub Med Coll Abbottabad. 2012;24(3–4):120–123.
- Mohammadi Pour P, Fakhri S, Asgary S, et al. The signaling pathways, and therapeutic targets of antiviral agents: focusing on the antiviral approaches and clinical perspectives of anthocyanins in the management of viral diseases. Front Pharmacol. 2019;10:1207. doi: 10.3389/fphar.2019.01207
- Tassakka A, Iskandar IW, Juniyazaki AB, et al. Green algae Caulerpa racemosa compounds as antiviral candidates for SARS-CoV-2: In silico study. Narra J. 2023 Jul;3(2):e179.
- Bioferon (Interferon Alfa): uses, side effects, interactions, Dosage/Pillintrip. Pillintrip. 2022. https://pillintrip.com/medicine/bioferon-interferon-alfa